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Abstract
 .Platelet-activating factor PAF acetylhydrolases are a family of distinct enzymes with the common property of
hydrolyzing and inactivating PAF. It has been shown that the structure and the biochemical behavior of these enzymes
depend on their cellular origin. We studied the PAF acetylhydrolase activity in mouse platelets in order to investigate the
unusual response of these platelets to PAF. We found that mouse platelets contain a PAF acetylhydrolase with an apparent
K value of 0.8 mM, suggesting a very high affinity for PAF. Contrary to other normal mammalian cells and tissues,m
mouse platelet PAF acetylhydrolase is almost equally distributed in the membranes and the cytosol and is characterized by
an extreme sensitivity to heating. The enzyme requires the presence of dithioerythritol for maximal activity, it is affected by
X  .5,5 -dithiobis 2-nitrobenzoic acid and N-ethylmaleimide, and it is strongly inhibited by phenylmethylsulfonylfluoride. We
purified, to near homogeneity, the PAF acetylhydrolase from mouse platelet membranes and demonstrated that it is a
protein relatively abundant in the membranes with an apparent molecular weight of 270 kDa. Electrophoretic analysis,
under reducing conditions, revealed four bands and one duplet with molecular weights of 66, 55, 52, 49 and 62 kDa,
respectively. Thus, PAF hydrolysis in mouse platelets is mediated by a PAF acetylhydrolase having biophysical and
biochemical properties more intricate than those of the PAF acetylhydrolases found in other species.
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1. Introduction
Platelet-activating factor PAF,1-0-alkyl-2-acetyl-
.sn-glycero-3-phosphocholine is a bioactive phospho-
 .Abbreviations: PAF platelet-activating factor , 1-0-hexade-
cyl-2-acetyl-sn-glycero-3-phosphocholine; PC, L-a-phosphati-
dylcholine; EDTA, ethylendiaminetetraacetic acid; DTNB, 5,5X-
 .dithio-bis 2- nitrobenzoic acid ; PMSF, phenylmethylsulfonyl-
fluoride; DMSO, dimethyl sulphoxide; DTE, dithioerythritol;
NEM, N-ethylmaleimide; DOC-Na, sodium deoxycholate;
w . xCHAPS, 3- 3-cholamidopropyl dimethilammonio -1-propane
sulfonate; SDS, sodium dodecyl sulfate; PAGE, polyacrylamide
gel electrophoresis; TCA, trichloracetic acid; DTT, dithiothreitol;
CMC, critical micellar concentration.
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lipid mediator, that appears to participate in patholog-
ical processes e.g., inflammation, allergy, asthma,
.acute bronchoconstriction as well as in physiological
 .events e.g., reproduction, blood pressure in several
 w x.species reviewed in Refs. 1–3 .
PAF in vitro can activate a variety of cells, includ-
ing platelets, neutrophils and macrophages and is
produced upon appropriate stimulation by many types
w xof cells and tissues 4,5 . Its inactivation occurs by
hydrolysis of the sn-2 acetyl group of the glycerol
backbone. The reaction is enzymatically catalyzed by
 .a PAF acetylhydrolase PAF-AH which appears to
be the key enzyme for regulating the extracellular
w xand intracellular levels of PAF 6–9 .
PAF-AHs have been detected in plasma, blood
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cells and tissues of various species and can be se-
creted by some types of cells for review, see Ref.
w x.10,11 . They appear to be a multi-component family
of enzymes that differ in their biochemical properties
even within the same species. PAF-AHs have been
w xpurified from human plasma 12 and erythrocytes
w x w x13 , from bovine brain 14 and more recently, from
w xbovine liver 15 . During the last decade, evidence
has accumulated which suggests that PAF-AH medi-
ates a protective mechanism against oxidative dam-
ages because, in addition to PAF, the PAF-AHs also
utilize, as substrates, toxic oxidatively fragmented
w xphospholipids 16,13–15 . Furthermore, changes in
the levels of plasma PAF-AH were observed in vari-
w x w xous diseases 10 . Recently, Tjolker et al. 17 pro-
posed that PAF-AH might be utilized in the therapy
of acute inflammation.
Our interest in mouse platelet PAF-AH originated
from the fact that mouse has a peculiar response to
PAF. Contrary to other species, mouse is very resis-
tant to PAF when this phospholipid is administered in
w xvivo 18 and moreover, mouse platelets do not re-
spond to PAF with aggregation, even after stimula-
 y3 .tion by high concentrations e.g., 5P10 M of this
w xagent 18,19 . We considered that this different be-
havior of mouse platelets to PAF could coexist with
other differences related to the intracellular
metabolism of this mediator.
In the present study, we found that mouse platelets
contain high levels of PAF-AH, which is almost
equally distributed in the cytosolic and the membrane
fractions. In order to investigate the role of this
enzyme in mouse platelets, we examined some of its
biochemical properties and purified, to near homo-
geneity, the PAF-AH from platelet membranes.
2. Materials and methods
2.1. Materials
w 3 x1-0-Hexadecyl-2- H acetyl-sn-glycero-3-phos-
w3 x .phocholine H acetyl-PAF, 7.1 Cirmmol was pur-
 .chased from DuPont NEN Boston, MA, USA . Un-
labeled 1-0-hexadecyl-2-acetyl-sn-glycero-3-phos-
 .phocholine PAF , egg yolk L-a-phosphatidylcholine,
Phenyl Sepharose CL-4B and CHAPS were from
 .Sigma Chemical Co. St. Louis, MO, USA . Super-
ose 6B and Sephadex G-200 were from Pharmacia
 .Fine Chemicals AB Uppsala, Sweden . Hydroxylap-
atite was from Bio-Rad. All the other reagents were
obtained from Sigma Chemical Co. St. Louis, MO,
. USA and the solvents from Merck Darmstadt, Ger-
.  .many , Carlo Erba Milan, Italy and Riedel-de Haen
 .Seelze, Germany .
2.2. Enzyme preparations
 .Male Swiss SWR mice 20–25 g were placed in
an atmosphere of diethyl ether until respiration ceased.
The thoracic cavity was immediately opened and
 .blood 0.8–1 ml was collected by cardiac puncture
through a 0.6 mm-gauge needle into a plastic syringe
 .containing EDTA 0.2 M in a ratio of 1 part EDTA
to 40 parts blood. Blood from four to five mice was
pooled and centrifuged at 250=g for 15 min at
room temperature to prepare the platelet-rich plasma
 .PRP . The platelets were isolated from PRP by
centrifugation at 1400=g for 15 min at 48C. The
pellet was suspended gently in 3 ml of Buffer A 50
 .mM Tris-HCl pH 7.4 , containing 0.1 M NaCl and 1
.mM EDTA . After centrifugation at 1400=g for 15
min at 48C, the supernatant was discarded and the
pellet was resuspended in Buffer A at a final concen-
tration of 2.0–3.0=109 plateletsrml. The platelet
preparation was tested for its ability to hydrolyze
exogenously added PAF. The platelets were then
sonicated at 48C for 18=25 s with a 25-s interval
 .using a sonicator MSE at an output setting of 4. The
resulting lysate, containing less than 1% unbroken
platelets, as was calculated by hematocytometric ob-
servation, was then centrifuged at 104 000=g for 60
min at 48C to obtain the cytosolic fraction super-
.  .natant and the total membrane fraction pellet . The
pellet was resuspended in Buffer A and homoge-
nized. Platelet cytosolic and total membrane fractions
could be stored at y808C for at least 4 months
without significant loss of enzymatic activity.
2.3. Enzyme assay
Determination of PAF-AH activity was carried out
w3 xusing H acetyl-PAF as substrate. The specific activ-
ity of the enzyme was expressed as nmol PAFrhrmg
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of protein. The protein concentration was measured
w xby the method of Bradford 20 , with bovine serum
albumin as the standard.
The incubation mixture consisted of 100 mM Tris-
 . w3 xHCl pH 7.4 , 1 mM EDTA, 30 mM H acetyl-PAF
 .spec. act. 30 000 cpmrnmol and the enzyme prepa-
ration, in a total volume of 200 ml. In assaying the
intact platelet PAF-AH activity, 100 ml of their
 8 .suspension 2=10 platelets were used. In the case
of solubilized membranes, the final CHAPS concen-
tration was 0.65 mM.
The kinetic parameters for hydrolysis of sn-2 ac-
etate by platelet lysate, total membrane and cytosolic
fractions were determined by varying the substrate
concentration between 0 and 40 mM. The effect of
various agents on PAF-AH activity, was assayed at a
standard concentration of 10 mM PAF.
Incubations were carried out for 30 min at 378C
and the reaction was stopped by adding 0.75 ml of
 .chloroformrmethanol 1:2, vrv according to Bligh
w xand Dyer 21 . For the separation of the two phases
the final ratio of the chloroformrmethanolrwater
 . w3 xwas adjusted to 1:1:0.9 vrv and the H acetate
generated by the hydrolysis of PAF was measured in
0.6 ml of the aqueous phase.
2.4. Purification of the PAF-AH from platelet mem-
branes
Solubilization of membranes: Platelet membranes
were isolated as described under enzyme preparations
and total membranes were obtained by combining the
platelet lysates of 50 mice. The total membrane
 . fraction 7.3 mg of protein suspended in Buffer A 5
.ml , was stirred for 60 min at 48C in the presence of
 .13 mM final CHAPS concentration CMC 10 mM .
The mixture was then centrifuged at 104 000=g for
60 min at 48C and the supernatant 6.1 mg of solubi-
.lized membrane protein was used for the purification
of PAF-AH.
Superose 6B column: The solubilized membranes
 . 5 ml were applied to a Superose 6B column 1.4=
.30 cm and the elution was carried out with Buffer B
  .10 mM Tris-HCl pH 7.4 containing 0.1 M NaCl, 1
.mM EDTA, 0.5 mM DTE and 0.65 mM CHAPS , at
 .a flow rate of 12.5 mlrh, at 48C. Fractions 0.7 ml
were collected and assayed for PAF-AH activity and
for protein content.
Phenyl Sepharose CL-4B column: The active frac-
 .tions 15 ml from the Superose 6B column were
pooled and loaded at room temperature on a Phenyl
 .Sepharose CL-4B column 1.25=2.5 cm which was
  .equilibrated with Buffer C 10 mM Tris-HCl pH 7.4
.containing 0.1 mM EDTA and 0.5 mM DTE , at a
flow rate of 6 mlrh. A stepwise elution was carried
out at 48C using increasing concentrations of 3.3, 6.5,
 .8, 10 and 13 mM CHAPS 6 ml each in Buffer C.
 .Fractions 0.6 ml were collected and assayed for
PAF-AH activity and for protein content.
 .Batch Hydroxylapatite: The active fractions 7 ml
from the Phenyl Sepharose CL-4B column were
pooled and stirred for 20 min at 48C with 50 mg
hydroxylapatite, previously equilibrated with Buffer
  .D 5 mM potassium phosphate pH 6.8 containing
.10 mM CHAPS . The activity was extracted stepwise
from the hydroxylapatite at 48C, with increasing con-
centrations of 5, 10, 50, 100, 150 and 200 mM
 .potassium phosphate 0.4 ml each in Buffer D. The
elution time was 15 min for each step. The active
 .fractions 1.8 ml were pooled and ultrafiltrated using
 .a YM-10 filter Amicon Corp.
Nati˝e-PAGE: The resulting enzyme preparation
after lyophilization was suspended in 50 mM Tris-HCl
 .pH 6.8 buffer containing 0.3 M sucrose and 0.025%
bromophenol blue. The final CHAPS concentration
was adjusted to 10 mM. Electrophoresis under non-
denaturing conditions was carried out by the method
w xof Davis 22 . Acrylamide solutions were made in 0.7
mM CHAPS and the running buffer in 0.5 mM
CHAPS. A 7.5% acrylamide gel was run at a con-
stant voltage of 150 V and then sliced into 0.4-cm
horizontal strips. The gel slices were incubated with
 .10 mM Tris-HCl buffer pH 7.4 for 36 h at 48C. The
supernatant was assayed for PAF-AH activity.
SDS-PAGE: 3.5 mg of protein extracted from the
gel slice corresponding to the peak of activity in the
native-PAGE, was precipitated by the DOC-TCA
w xmethod 23 . Then 20 ml of sample buffer containing
 .50 mM Tris-HCl pH 6.8 , 0.3 M sucrose, 2% SDS
and 0.025% bromophenol blue was added to the
precipitate and the mixture was incubated for 10 min
at 958C. SDS-PAGE with an acrylamide concentra-
tion of 7.5%, was performed as described by Laemmli
w x24 . After electrophoresis at a constant voltage of
150 V, proteins were stained with silver nitrate.
In order to detect the existence of enzyme subunits
( )A.P. Karpouza, C. Vakirtzi-LemoniasrBiochimica et Biophysica Acta 1323 1997 12–22 15
SDS-PAGE, under reducing conditions, was per-
formed. One mg of the same preparation was precipi-
tated as mentioned above, solubilized in the same
sample buffer supplemented with 50 mM DTT and
run on a 7.5% acrylamide gel, under the same condi-
tions. Proteins were visualized by silver nitrate stain-
ing.
3. Results
3.1. Kinetic studies of mouse platelet PAF-AH
We studied the kinetic parameters of PAF-AH in
the platelet lysate, total membrane and cytosolic frac-
tions. Control experiments for PAF-AH activity in
intact platelets did not show any detectable PAF
hydrolysis. For the lysate, as well as for the total
membrane fraction of mouse platelets, PAF hydroly-
sis was linear up to 7 mg of protein and for an
incubation time of up to 45 min. For the cytosolic
fraction, PAF hydrolysis was linear for up to at least
30 mg of protein and for an incubation time of up to
60 min. The rate of PAF hydrolysis followed
Michaelis Menten kinetics for all three enzyme
preparations.
The apparent K and V values were calculatedm ma x
from the Lineweaver-Burk double reciprocal plot. For
the lysate, membrane and cytosolic preparations, the
apparent K values were 0.96"0.12, 0.85"0.22m
and 0.83"0.14 mM and the V values were 62, 88ma x
 .and 45 nmolrhrmg, respectively Table 1 .
The relative distribution of the total PAF-AH ac-
tivity, in the total membrane and cytosolic fractions,
was found to be 57% and 43%, respectively, as
calculated from the V values and the proteinma x
 .content of the two fractions Table 1 .
3.2. Biochemical properties of mouse platelet PAF-
AH
Table 2 summarizes the influence of various com-
pounds on platelet PAF-AH activity in both the cy-
tosolic and the total membrane fractions. In general,
no significant differences were observed between the
two enzyme preparations.
In order to determine whether PAF-AH has similar
properties to PLA , agents that influence the activity2
of typical PLA were added. Ca2q inhibited PAF-AH2
activity while the divalent metal chelator, EDTA,
increased, slightly, PAF hydrolysis. Moreover, the
addition of egg phosphatidylcholine, even at 100 mM
 .i.e., at a 10 times higher PAF concentration , caused
a slight inhibition of PAF hydrolysis that is appar-
ently due to the high lipid concentration in the incu-
w xbation mixture 25 .
Platelet PAF-AH was affected by Mg2q to the
same extent as Ca2q, while Mn2q was more in-
hibitory, and heavy metal ions, such as Cd2q and
Zn2q at 10 mM, poisoned the enzyme, in accordance
w xto their effect in the human erythrocyte enzyme 26 .
NaF, an inhibitor of PLA , at 10–20 mM seems to2
have no significant effect on PAF hydrolysis. It has
been reported that the effect of NaF on PAF-AH
w xdepends on its cellular origin 27 .
We then tested the effect of various agents that
inactivate enzymes containing essential sulfhydryl
groups. DTNB caused an apparently constant inhibi-
 .tion over a wide range of concentrations 0.1–2 mM
and NEM at 2 mM inhibited PAF hydrolysis to the
Table 1
Kinetic parameters and distribution of PAF acetylhydrolase activity in mouse platelets
)Cellular preparation K V Total protein Total activity Distribution ofm ma x
 .  .  .  .  .mM nmolrhrmg mg nmolrh activity %
Lysate 0.96"0.12 62 9.12 565 100
Membranes 0.85"0.22 88 3.64 320 57
Cytosol 0.83"0.14 45 5.48 247 43
Preparations of platelet lysate, membranes and cytosol containing 5, 5 and 10 mg of protein, respectively, were incubated for 30 min at
w3 x  .378C in the presence of H acetyl-PAF 0–40 mM as described in Section 2. K and V values were estimated from them ma x
Lineweaver-Burk double reciprocal plots. ) K values are the means"SD from 3 independent experiments.m
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same extent as DTNB at 2 mM, while DTE stimu-
lated PAF-AH. PMSF, a serine hydrolase inhibitor
w xfor the cytosolic form of PAF-AH 8 , inhibited
mouse platelet PAF-AH in a concentration-dependent
manner. Finally, the enzymatic activity was strongly
affected by anionic detergents such as DOC-Na CMC
.  .4–8 mM and SDS CMC 8.2 mM , at concentrations
much lower than their CMC value; however, it was
less sensitive to the non ionic detergent Triton X-100
 .CMC 0.25 mM .
3.3. Purification of PAF-AH from platelet membranes
The unusually high percentage of PAF-AH activity
present in platelet membranes led us to utilize the
total membrane fraction of mouse platelets for the
subsequent purification of the PAF-AH. Among the
various detergents examined for their ability to solu-
bilize platelet membranes and their inhibitory effect
on the solubilized enzyme, CHAPS at 13 mM CMC
.10 mM , proved to be the most effective. The yield
of solubilized protein was 84% and subsequent dilu-
 .tion 20-fold of the solubilized preparation was nec-
essary to obtain the optimal conditions for assaying
PAF-AH activity. Under these conditions, a 70–75%
solubilization of the total activity found in platelet
membranes, was recovered.
Due to the small quantity of blood per animal, the
purification procedure was performed with a very
 .low initial amount of solubilized protein 6.1 mg .
We therefore chose this specific series of column
purification steps, in order to avoid multiple dialyses
 .Fig. 1. Purification steps of platelet total membrane fraction PAF acetylhydrolase. A Superose 6B. After solubilization with CHAPS, the
 .  .total membrane fraction 6.1 mg of solubilized protein was loaded on a Superose 6B column. Fractions 1 ml were collected and
 .  .assayed for activity and for protein content. B Phenyl Sepharose CL-4B. The active fractions 15 ml from the Superose 6B column
 .  .were loaded on a Phenyl Sepharose CL-4B column. Fractions 0.7 ml were collected and assayed for activity and for protein content. C
 .Hydroxylapatite batch. The active fractions 7 ml from the Phenyl Sepharose column were mixed with 50 mg of Hydroxylapatite and
 .elution was performed stepwise, with increasing concentration of phosphate buffer. Fractions 0.4 were collected and assayed for PAF
 .  .acetylhydrolase activity. D Native-PAGE. The active fractions 1.8 ml from the Hydroxylapatite were pooled, ultrafiltrated and placed
on a gel of 7.5% acrylamide. After electrophoresis the gel was sliced into horizontal strips, which were extracted and assayed for PAF
acetylhydrolase activity.
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Table 2
Effect of various agents on mouse platelet PAF acetylhydrolase
activity
Addition Concentration PAF acetylhydrolase activity
 .  .mM % of control
Membranes Cytosol
CaCl 1 82 772
2 72 ND
10 62 71
EDTA 1 117 ND
2 116 ND
10 113 ND
aPC 0.02 99 88
0.1 86 65
MgCl 10 66 722
MnCl 10 48 462
CdCl 10 7 172
ZnCl 10 2 22
NaF 10 97 97
20 88 89
DTNB 0.1 77 83
0.5 82 85
1 72 77
2 59 63
NEM 2 64 69
DTE 5 137 149
aPMSF 0.1 34 45
0.5 17 18
1 13 14
2 7 11
DOC-Na 1 74 62
2 22 23
4 4 4
SDS 0.35 ND 38
1.73 ND 4
Triton X-100 0.16 92 90
1.6 38 ND
Preparations of platelet membranes and cytosol containing 5 and
10 mg of protein, respectively, were preincubated with the vari-
w3 xous agents for 5 min at 378C. After addition of H acetyl-PAF at
a final concentration of 10 mM, the incubation was continued for
30 min and PAF acetylhydrolase activity was assayed as de-
scribed in Section 2. Control activity in these experiments was 48
nmolrhrmg for the membranes and 31 nmolrhrmg for the
cytosol. Results are the means of two independent experiments
performed in duplicate. ND, not determined.a PC was dissolved
in ethanol and PMSF in DMSO. Any effects due to solvents have
been subtracted.
and ultafiltrations, which rendered the solubilized
membranes unstable e.g., at CHAPS concentrations
.below 0.3 mM, a protein precipitate was observed .
Fig. 1 shows the purification procedure of the
PAF-AH from the platelet membranes. The solubi-
lized membrane fraction was first loaded onto a
 .Superose 6B gel filtration column Fig. 1A . The
active peak fractions from the size exclusion step
were pooled and applied to a hydrophobic Phenyl
Sepharose CL-4B column at room temperature, which
was operated at 48C. Under these conditions the
PAF-AH activity was completely retained on the
column. Most of the contaminating proteins were
either not bound to the resin or eluted stepwise with a
buffer containing CHAPS, at a concentration of 3.3–8
mM. The enzyme was eluted as a single sharp peak
 .with 10 mM CHAPS Fig. 1B , suggesting the ex-
tremely hydrophobic nature of the mouse platelet
PAF-AH. The subsequent hydroxylapatite batch elu-
tion step was performed in the presence of 10 mM
 .CHAPS Fig. 1C , because in lower CHAPS concen-
trations, the activity was not eluted from the hydrox-
ylapatite, even at 600 mM potassium phosphate. The
active fractions from the batch hydroxylapatite step
after ultrafiltration and lyophilization were subjected
to a 7.5% polyacrylamide gel electrophoresis under
 .non-denaturing conditions Native-PAGE , in the
presence of CHAPS. Under these conditions PAF-AH
activity was recovered as a single sharp peak with an
 .Rf value of 0.12 Fig. 1D . In this step, a significant
Fig. 2. SDS-PAGE in 7.5% acrylamide, under non-reducing
conditions of the purified membrane-associated PAF acetylhydro-
lase of mouse platelets. Lanes 1 and 3, molecular weight markers
 .kDa . Lane 2, 3.5 mg of the purified product. Proteins were
stained with silver nitrate.
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Fig. 3. SDS-PAGE in 7.5% acrylamide, under reducing condi-
tions of the purified PAF acetylhydrolase from platelet mem-
branes. Lane 1, 1 mg of the purified product. Lane 2, molecular
 .weight markers kDa . Proteins were stained with silver nitrate.
loss of the activity was observed. Subsequent SDS-gel
electrophoresis 7.5% acrylamide and non-reducing
.conditions of the active peak showed a single protein
band with an estimated molecular weight of 270 kDa
 .Fig. 2 . Under reducing conditions as described in
Section 2, this protein band was resolved into four
bands and one duplet with estimated molecular
weights of 66, 55, 52, 49 and 62 kDa, respectively
 .Fig. 3 . The summary of the purification procedure
is shown in Table 3.
3.4. Effect of temperature on PAF-AH
The PAF-AH activity of the final purification
product decreased with temperature; it was reduced
by 85% after a 10-min preincubation period at 608C
 .Fig. 4A . Similar thermolability was observed for
Fig. 4. Inactivation of PAF acetylhydrolase as a function of
 .  .temperature A or preincubation time at 378C B . A preparation
 .of the final purification product 0.2 mg of protein was preincu-
 .bated for 10 min at the indicated temperature A or for the
 . w3 x  .indicated time at 378C B . Then H acetyl-PAF 10 mM was
added and PAF acetylhydrolase was assayed as described in
Section 2. The inactivation of PAF acetylhydrolase activity in
 . crude membrane 5 mg of protein and cytosolic 10 mg of
.protein preparations of mouse platelets were also included for
comparison. Control activity in these experiments was 342, 52
and 44 nmolrhrmg for the purified product, the membranes and
the cytosol respectively.
Table 3
Purification of PAF acetylhydrolase from mouse platelet membranes
Step Protein Specific activity PurificationTotal activity
 .  .mg nmolrhrmgnmolrh %
Lysate 19.10 1112 58.2
104 000=g pellet 7.30 638 87.4
Solubilized membranes 6.13 460 100 75.0 1
Superose 6B 3.32 611 133.0 184 2.5
Phenyl Sepharose CL-4B 0.43 327 71.1 761 10.1
Hydroxylapatite 0.25 250 60.9 1000 13.3
Ultrafiltration 0.091 144 31.3 1586 21.1
Native-PAGE 0.028 16.5 3.6 588
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Fig. 5. Effect of DTE on PAF acetylhydrolase activity as a
function of time. A platelet membrane preparation containing 5
mg of protein was preincubated with 5 mM DTE for the indicated
 . w3 x  .time 0–30 min at 378C. Then H acetyl-PAF 10 mM was
added and the PAF acetylhydrolase activity was assayed as
described in Section 2. Control activity in open bars and activity
after treatment with DTE in hatched bars.
the crude membrane and cytosolic preparations of
 .mouse platelets Fig. 4A . Fig. 4B shows the loss of
the activity as a function of preincubation time at
378C. There was a similar decrease of the activity for
the membrane and the cytosolic fraction of mouse
platelets and a 50% loss of the enzymatic activity
was observed when the preincubation was carried out
for 30 min. The purified product was significantly
more susceptible to temperature inactivation since
50% of the enzymatic activity was already lost after
preincubation for 5 min at 378C and only 27% of the
activity was retained after 30 min at this temperature.
The presence of reducing agents, such as DTE 5
.mM , in the crude preparation of platelet membranes,
in spite of the induced enhancement of the enzymatic
activity, was not able to protect the enzyme from the
 .temperature inactivation Fig. 5 . The rate of the
enzymatic activity loss was the same, in the presence
or absence of DTE, suggesting that temperature af-
fects the structure of the enzyme as a whole, rather
than groups, essential for the enzymatic activity.
Fig. 6. Densitogram of the solubilized mouse platelet membranes. A preparation of solubilized platelet total membrane fraction,
 .containing 65 mg of protein, was subjected to SDS-PAGE 10% acrylamide, under non-reducing conditions , as described in Section 2.
Peak 1 corresponds to the band having a molecular weight of 270 kDa.
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3.5. Densitometric analysis of platelet membrane pro-
teins
Fig. 6 shows the profile of a solubilized membrane
preparation on SDS-PAGE, performed in 10% acryl-
amide under non-reducing conditions and its densito-
metric analysis. The intensity of the band which
corresponds to the molecular weight of 270 kDa, the
estimated molecular weight of the PAF-AH, was
found to constitute approx. 2.3% of the total
Coomassie-stained protein.
4. Discussion
In this work we demonstrated that mouse platelets
contain PAF-AH activity, which is present to the
extent of 57% in the total membrane fraction and
43% in the cytosol. This finding is in contrast with
other blood cells and tissues of the various species
studied to date, in which PAF-AH activity has been
w xfound mainly in the cytosol 10,11 . Nevertheless, in
the protozoan Tetrahymena pyriformis most of the
w xactivity was detected in the microsomal fraction 28
and furthermore, in Ehrlich ascites cells, increased
w xactivity was found in the microsomes 29 . Further-
more a particulate fraction-associated PAF-AH activ-
ity has been reported in HL-60 cells and an increase
in its relative distribution to this fraction during
w xdifferentiation has been observed 30 . As for the
platelets of other species, the presence of PAF-AH
activity in their membrane fraction has not to date
been investigated.
The very low apparent K value of 0.8 mM form
both the membrane-associated and the cytosolic en-
 .zymatic activity Table 1 , suggests the presence of
the same enzyme with a very high affinity for PAF in
both fractions. The similarity of response of the two
 .enzyme preparations towards temperature Fig. 4
 .and various agents Table 2 , is consistent with such
a suggestion. The small differences observed for
certain compounds, e.g., Ca2q and PC, might be
attributed to the different environment of the enzyme
in these two fractions.
Mouse platelet PAF-AH is an enzyme totally dif-
ferent from the typical cytosolic or membrane-bound
 .PLA , as is shown from: a its inhibition rather than2
its activation by Ca2q and its slight stimulation by
 .EDTA, b its failure to hydrolyze phosphatidyl-
 . w xcholine and, c its sensitivity at 378C 31 . We
cannot exclude the possibility that the inhibition by
Ca2q and the stimulation by EDTA may be due to
2q w xCa -dependent proteases present in platelets 32 .
The enzyme does not seem to be a lysophospho-
lipase. This is supported by the lower K valuem
towards PAF, compared to the lysophospholipase II
w xisolated from bovine liver 33 . Moreover, the re-
sponse to PMSF, NEM and metal ions differentiates
this enzyme from the lysophospholipases of the type
w xisolated from mouse macrophages 34 . It is worth
mentioning that in the case of human and rat platelets,
PAF-AH and lysophospholipase activities harbor dif-
ferent proteins, as has been reported by Aarsman et
w xal. 33 .
The effect of the sulfhydryl agents DTNB, NEM
and DTE suggests that the platelet enzyme contains
essential sulfhydryl groups and requires the addition
of reducing agents for maximal activity. The sensitiv-
ity to PMSF suggests the presence of serine residues
at the active site. The inhibitory effect of Triton
X-100 when the PAF concentration was 10 mM, well
 . w xabove its CMC 2.5–3 mM 35 , could be due to the
surface dilution kinetic effect, described by Stafforini
w xet al. 12,13 . Anionic detergents such as DOC-Na
and SDS, at concentrations much lower than their
CMC, apparently denature the enzyme, possibly by
affecting its tertiary and quaternary structure.
We purified, to near homogeneity, the PAF-AH
from mouse platelet membranes. The final purifica-
tion product gave, on SDS-PAGE, one band with an
 .apparent molecular weight of 270 kDa Fig. 2 . This
band, under reducing conditions, was resolved into
four well separated bands and one duplet with molec-
ular weights of 66, 55, 52, 49 and 62, kDa, respec-
 .tively Fig. 3 . At this point though, we do not know
which of these polypeptides functions as the catalytic
site.
The mouse platelet PAF-AH is characterized by an
 .extreme sensitivity at 378C Fig. 4B , since a 73%
loss of its activity was observed after a 30-min
preincubation period at 378C. In addition, the mouse
platelet enzyme is more susceptible to inactivation at
 . w x608C Fig. 4A from the erythrocyte enzyme 13 .
The instability of mouse platelet PAF-AH, in the
crude as well as in the purified preparation, at 378C
was a major problem in the estimation of its actual
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specific activity in every step of the purification
 .procedure. Thus the extent of purification Table 3
based on specific activity can only serve as an indica-
tive marker of this procedure. The final purification
 .fold 21 was calculated from the step prior to
native-PAGE, because during this step a significant
loss of the activity was observed, as it has been
w xreported by Stafforini et al. 13 for the PAF-AH of
w xhuman erythrocytes. Moreover Aarsman et al. 33
reported that the recovery of the PAF-AH activity
residing in the bovine liver lysophospholipase II was
very low, less than 10%, following nondenaturing gel
 .electrophoresis. Our final product 28 mg constitutes
 .0.5% of the total initial solubilized protein 6.1 mg
 .Table 3 . This fact suggests that the enzyme is
abundant in mouse platelet membranes. The densito-
metric analysis of the crude solubilized preparation
 .after SDS-PAGE Fig. 6 further supports such a
suggestion. Therefore, the instability of the enzyme
during the purification procedure and the fact that the
purification was performed using a starting material
already rich in the enzyme, resulted in a final prepa-
ration with a low specific activity and consequently a
low purification fold. However, the homogeneity of
the final preparation as to its PAF-AH content, seems
 .to be approx. 100% Fig. 2 .
From the above, we may conclude that mouse
platelet PAF-AH is an enzyme different from the
PAF-AHs of normal mammalian cells examined so
 .far. This is supported by the following points: a the
high concentration of the enzyme in the membranes,
 .  .b the very low K value, and c its thermolability.m
In addition the 270 kDa mouse platelet PAF-AH is a
protein of higher molecular weight and of a more
complex structure than those of the PAF-AHs iso-
w xlated from other cells and tissues 12–15 . However,
the PAF-AHs in the platelets of other species have
not been investigated to date and as such, molecular
weight comparisons cannot be directly made. More-
over, mouse platelet PAF-AH is an enzyme with
properties distinct from the mainly HDL-associated
plasma enzyme as is shown by their different K ,m
response to various agents, thermosensitivity, molec-
w xular weight and structure 36 . We may mention,
however, that the 62 kDa polypeptide of the platelet
PAF-AH has the same molecular weight with one of
w xthe mouse plasma enzymes 36 . Despite the above
noted differences, mouse platelet enzyme does share
some properties with other cellular and tissue PAF-
AHs, e.g., the presence of essential sulfhydryl groups
and the strong inhibition by serine hydrolase in-
hibitors, such as PMSF.
The unexpected presence of PAF-AH activity in
platelet membranes led us to examine the possibility
of its loose association with the membranes under our
experimental conditions. Successive treatments of
platelet membranes with a high ionic strength buffer
 .buffer A, containing 0.5 M NaCl , not only failed to
extract the PAF-AH from the membranes, but further
increased its specific activity by 100%. This observa-
tion suggested that the PAF-AH activity was proba-
bly firmly associated with the platelet membranes.
Given its presence in both cellular compartments,
membranes and cytosol, it remains unknown whether
there is a mechanism that allows the migration of the
enzyme between these two compartments. We also
cannot exclude the possibility that mouse platelet
PAF-AH is a membrane-bound enzyme which during
sonication, the most effective manner of platelet dis-
ruption in our hands, is partially solubilized into the
cytosol, as is the case with other membrane-bound
w xenzymes 37 .
Intact mouse platelets do not hydrolyze exoge-
nously added PAF, suggesting that PAF-AH or its
.active site is not localized at the outer surface of the
platelet membrane and it is not released in the
medium. Moreover, mouse platelets, when stimulated
by thrombin, do not biosynthesize PAF unpublished
.data . Thus, the following two questions arise: what
is the role of the high levels of PAF-AH in mouse
platelets and what is the significance of its presence
in both cytosol and membranes? It could be sug-
gested that mouse platelet PAF-AH utilizes as sub-
strates, in addition to PAF, other PAF-like lipids or
oxidized phospholipids, as has been reported in the
w xcase of several cells and tissues 16,13–15 , and
which in this case could be localized in different
cellular compartments. Another possibility, which
may explain the high concentration of the PAF-AH in
mouse platelets and its high molecular weight, is that
the enzyme constitutes a functional domain of a
multifunctional protein or a multi-enzyme complex.
The analysis of the PAF-AH on SDS-PAGE under
 .reducing conditions into six polypeptides Fig. 3
could support such a hypothesis. Thus, the investiga-
tion of the cellular compartmentalization of the PAF-
( )A.P. Karpouza, C. Vakirtzi-LemoniasrBiochimica et Biophysica Acta 1323 1997 12–2222
AH, its structure and its cellular substrates, other than
PAF, are necessary for the understanding of the role
of this enzyme in mouse platelets.
This is the first report of a purified PAF-AH
associated with the membranes of a normal mam-
malian cell. Our work does not address directly the
problem of the mouse platelet refractoriness to PAF
w x18 . Nevertheless the finding that the PAF-AH is
found not only in the cytosol but also bound to the
membranes, may finally provide the basis for ap-
proaching the problem of mouse and rat platelet
w xnonresponsiveness to PAF 18,38 .
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